Nathan Bahary

机构：Allegheny Health Network · ORCID：0000-0001-7317-9118

发表论文 273 篇 · 总被引 20960 次 · h-index 58

代表论文

• Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (2024 · Annals of Oncology · 被引 329)
• Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium (2023 · Journal of Clinical Oncology · 被引 72)
• Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study (2024 · Journal of Clinical Oncology · 被引 40)
• Defining the Values and Quality of Life of Cancer Survivors Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An International Survey Study (2023 · Annals of Surgical Oncology · 被引 12)
• Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial (2023 · ESMO Open · 被引 11)
• ARC-8: Phase 1/1b randomized study of quemliclustat + gemcitabine/nab-paclitaxel ± zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma. (2024 · Journal of Clinical Oncology · 被引 8)